HER2 Gene News and Research

RSS

The HER2 (human epidermal growth factor receptor 2) gene is part of a family of genes that play roles in regulating cell growth. The protein it makes is a tyrosine kinase growth factor receptor that a number of normal tissues express and which probably has a role in normal cell function, regulating growth and proliferation.

New drug added to chemo kills off residual breast cancer stem cells

New research says chemotherapy often fails to totally eliminate breast cancer because it does not knock out breast cancer stem cells.

30 Apr 2008

Getting to the roots of breast cancer

The lesson learned in eradicating dandelions from your yard could apply in treating breast cancer as well, said researchers from Baylor College of Medicine in Houston in a report that appears online today in the Journal of the National Cancer Institute.

29 Apr 2008

Combo of Herceptin and chemo a cure for breast cancer

The latest research has shown that the combination of Herceptin and chemotherapy drugs is successful in treating women with aggressive breast cancer.

22 Apr 2008

Herceptin and chemotherapy improves response rates without major adverse effects in HER2 breast cancer

Women with a particularly aggressive form of breast cancer seem to do better if they are treated with a combined anthracycline and taxane chemotherapy regimen before surgery, together with trastuzumab (Herceptin) before and after surgery, according to results from the largest multi-centre trial to investigate this treatment.

18 Apr 2008

Biomarkers allow doctors to match therapy to patient

Genetic variations ensure that no two people are exactly alike, nor are their cancers.

13 Apr 2008

Triple-negative breast cancers doesn't always mean cancer spread

Triple-negative breast cancers are a heterogeneous group and may not always be associated with lymph node spread, a new study shows.

13 Apr 2008

Modified virus vaccine shows promise in mouse model of breast cancer

Researchers have shown that vaccinating mice with a modified form of a virus containing proteins from breast cancer cells can kill large breast cancer tumors and tumors that have spread to the lungs.

17 Mar 2008

Nuclear protein SATB1 triggers aggressive breast cancer

SATB1 is a nuclear protein well known for its crucial role in regulating gene expression during the differentiation and activation of T cells, making it a key player in the immune system.

13 Mar 2008

Cardiac effects associated with breast cancer treatment appear lower with dose-dense chemotherapy

A new pilot study by investigators at Memorial Sloan-Kettering Cancer Center (MSKCC) found that breast cancer patients can be treated safely with a "dose-dense" regimen of standard chemotherapy agents and the antibody trastuzumab (Herceptin), a drug that has previously been shown to cause cardiac toxicity.

11 Mar 2008

Cardiac effects associated with breast cancer treatment appear lower

A new pilot study by investigators at Memorial Sloan-Kettering Cancer Center (MSKCC) found that breast cancer patients can be treated safely with a “dose-dense” regimen of standard chemotherapy agents and the antibody trastuzumab (Herceptin®), a drug that has previously been shown to cause cardiac toxicity.

10 Mar 2008

New global study of targeted therapies for breast cancer

Two targeted medications designed to treat an aggressive form of breast cancer are being tested in a new study involving 8,000 participants in 50 countries across six continents -- a clinical trial that investigators hope will provide a new model for global cancer research.

1 Mar 2008

Breast cancer subtypes linked to survival from secondary brain tumors

Screening breast cancers for three receptors could help doctors predict the likely survival of patients with brain metastases.

28 Feb 2008

New method for detecting HER2 breast cancer

Generations of mothers have served up chicken soup to remedy the common cold, but now the therapeutic fowl may find use in diagnosis as well.

21 Feb 2008

Anthracyclines improve survival in HER2-positive breast cancer patients

Treatment with the class of chemotherapy drugs called anthracyclines improves survival in women with HER2-positive breast cancer who have previously had surgery, but it may not offer any benefit for women with HER2-negative tumors, according to a study published online December 25 in the Journal of the National Cancer Institute.

28 Dec 2007

Combo therapy reduces size of brain tumours

According to a major drug manufacturer, a combination drug treatment appears to be effective in fighting breast cancer that has spread to the brain.

19 Dec 2007

Survival shortened when estrogen or progesterone receptor negative breast cancer spreads to the brain

Two studies from Mayo Clinic's site in Jacksonville, Fla., of women whose breast cancer spread to their brain, have found that women whose tumors do not have estrogen or progesterone receptors have the worst overall outcomes.

17 Dec 2007

Herceptin helps women with multiple chromosomes containing HER2 gene

The targeted therapy Herceptin helps women with HER2+ type of breast cancer independent of whether patients have extra copies of chromosome 17, home to the HER2 gene which produces the HER2 protein that fuels cancer growth.

17 Dec 2007

Tumors less than 1 centimeter in size can be aggressive and may require maximum therapy

Breast tumors that are 1 centimeter in size or smaller - no more than 0.4 inch in length - can still be very aggressive and may require more intensive therapy than is routinely offered today, say researchers at Mayo Clinic in Jacksonville, Fla.

17 Dec 2007

Targeted therapy and chemotherapy shrinks breast cancer metastases in brain

A combination of a "targeted" therapy and chemotherapy shrank metastatic brain tumors by at least 50 percent in one-fifth of patients with aggressive HER2-positive breast cancer, according to data presented by Dana-Farber Cancer Institute investigators at the San Antonio Breast Cancer Symposium.

17 Dec 2007

Study shows how mutations in the BRCA1 gene lead to breast cancer

An international team of researchers led by Columbia University Medical Center's Herbert Irving Comprehensive Cancer Center and Sweden's Lund University has, for the first time, revealed how mutations in the BRCA1 gene lead to breast cancer.

10 Dec 2007